Contact the bigtimepeptides Desk

Editorial correspondence

This site welcomes notes on the record itself: a citation quoted imprecisely, a trial that has since posted new results, a compounding-pharmacy access category that's changed, or a peer-reviewed study on sermorelin, tesamorelin, or ipamorelin that belongs on the references page. The most useful messages name three things — which page, the exact passage in question, and the supporting source, with a DOI or PubMed ID where you have one. That's enough to check a proposed correction against its source before anything changes.

Editorial mailbox: editors@bigtimepeptides.com

What this desk can't do

Because bigtimepeptides reports the research literature rather than practicing medicine or selling anything, a few kinds of requests fall outside what this desk can answer: it can't recommend a dose, schedule, or route for any individual; it can't judge whether a finding from a cited trial applies to a specific person's situation; and it can't point toward a supplier or source for any of the three compounds, whether prescription (tesamorelin), compounded (sermorelin), or research-grade (ipamorelin). Anyone seeking clinical guidance should bring the question to a licensed clinician in their own jurisdiction — tesamorelin in particular is a prescription medicine available only through a licensed provider for its approved indication. Replies aren't guaranteed and can take a while; the mailbox is checked periodically.